Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimodivir - Janssen Pharmaceuticals

Drug Profile

Pimodivir - Janssen Pharmaceuticals

Alternative Names: JNJ-3872; JNJ-63623872; JNJ-872; VX 787

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Janssen Pharmaceuticals; Vertex Pharmaceuticals
  • Class Antivirals; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Influenza A virus infections

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Influenza-A-virus-infections(In volunteers) in Belgium (IV, Infusion)
  • 16 Jul 2019 Johnson & Johnson announces intention to submit NDA and MAA in USA and European Union, respectively, for Influenza A virus infections, between 2019 and 2023 (Johnson & Johnson pipeline, July 2019)
  • 02 Jul 2019 Janssen-Cilag International initiates a phase I pharmacokinetic trial (In volunteers) in Germany (PO) (NCT03947814)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top